Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($3.07), $0.37 better than the analyst estimate of ($3.44). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $5.17 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.